Breaking News Instant updates and real-time market news.

RL

Ralph Lauren

$78.15

(0.00%)

, CBS

CBS

$64.52

(0.00%)

09:21
08/08/17
08/08
09:21
08/08/17
09:21

On The Fly: Pre-market Movers

UP AFTER EARNINGS: Ralph Lauren (RL), up 8.3%... CBS (CBS), up 1.1%... Michael Kors (KORS), up 17.9%... Endo (ENDP), up 3.8%. DOWN AFTER EARNINGS: CVS Health (CVS), down 1.4%... Wayfair (W), down 1.3%... SeaWorld (SEAS), down 19.5%... Dean Foods (DF), down 13.2%.

RL

Ralph Lauren

$78.15

(0.00%)

CBS

CBS

$64.52

(0.00%)

KORS

Michael Kors

$37.23

(0.00%)

ENDP

Endo

$9.31

-0.07 (-0.75%)

CVS

CVS Health

$79.12

(0.00%)

W

Wayfair

$80.57

(0.00%)

SEAS

SeaWorld

$13.61

(0.00%)

DF

Dean Foods

$14.97

(0.00%)

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 08

    Aug

  • 09

    Aug

  • 10

    Aug

  • 17

    Aug

  • 07

    Sep

  • 21

    Sep

  • 22

    Sep

RL Ralph Lauren
$78.15

(0.00%)

07/18/17
NEED
07/18/17
INITIATION
NEED
Hold
Ralph Lauren initiated with a Hold at Needham
07/17/17
BUCK
07/17/17
INITIATION
Target $68
BUCK
Neutral
Ralph Lauren assumed with a Neutral at Buckingham
Buckingham analyst Eric Tracy assumed coverage of Ralph Lauren with a Neutral rating and $68 price target.
04/20/17
OTRG
04/20/17
DOWNGRADE
OTRG
Negative
Ralph Lauren downgraded to Negative from Mixed at OTR Global
OTR Global downgraded Ralph Lauren to Negative saying checks indicate US outlets were hurt by a downturn in traffic and late winter storms in Q4 and orders for July-September are flat to down year-over-year among woman buyers.
05/25/17
TIGR
05/25/17
INITIATION
TIGR
Neutral
Ralph Lauren initiated with a Neutral at Tigress Financial
Tigress analyst Ivan Feinseth initiated Ralph Lauren with a Neutral saying business performance continues to deteriorate at a rapid pace due to changes in consumer preference and retail industry headwinds.
CBS CBS
$64.52

(0.00%)

07/10/17
JEFF
07/10/17
NO CHANGE
Target $71
JEFF
Buy
CBS shares are undervalued, says Jefferies
CBS will be increasingly viewed as a multi-platform content creator rather than simply "the network," Jefferies analyst John Janedis tells investors in a research note. The analyst believes that CBS by 2020 will generate an incremental $2.00-plus per share in earnings from retrans, Showtime over-the-top and All Access. He views the stock as undervalued at current levels and keeps a Buy rating on the name with a $71 price target.
05/19/17
RBCM
05/19/17
NO CHANGE
RBCM
CBS is predator and prey,' says RBC Capital
As the situation deteriorates for media companies due to accelerating cord cutting and weak ad trends, RBC Capital analyst Steven Cahall thinks that companies in the sector will look to consolidate.He believes that CBS (CBS) could buy Lionsgate (LGF.A,LGF.B) in a deal that would be 5% accretive and be viewed favorably by the market or the TV network could be acquired by Verizon (VZ). However, the analyst thinks the most likely scenario is an acquisition of Viacom (VIAB) by CBS.
05/15/17
LOOP
05/15/17
NO CHANGE
Target $76
LOOP
Buy
CBS in 'enviable position' ahead of upfront presentation, says Loop Capital
Loop Capital analyst David Miller noted that CBS will finish as the number one network in total viewers for the fourteenth time in fifteen years when the 2016-2017 broadcast season ends this month and that the company's flagship network has no "glaring weakness" within any day or day-part. This makes CBS the one broadcast or cable network that has real leverage over media buyers as "upfront" negotiations begin next week, said Miller, who keeps a Buy rating and $76 price target on CBS shares.
06/27/17
PIPR
06/27/17
NO CHANGE
Target $75
PIPR
Overweight
CBS profits should expand by 53% by 2020, says Piper Jaffray
Piper Jaffray analyst Stan Meyers says his analysis indicates CBS's profits should expand by 53% by 2020, with margins improving to 27% from 22%, as the company repositions itself as a content monetization engine versus its ad-dependent past. He notes that his estimates over the next four years are ahead of consensus. The analyst sees a "great entry point ahead of a number of catalysts" and keeps an Overweight rating on CBS shares with a $75 price target.
KORS Michael Kors
$37.23

(0.00%)

07/31/17
07/31/17
DOWNGRADE
Target $45

Hold
Coach downgraded to Hold from Buy at Jefferies
Jefferies analyst Randal Konik downgraded Coach (COH) to Hold citing valuation. The company's recovery is playing out, "but everyone knows it," Konik tells investors in a research note. The analyst lowered his price target for Coach shares to $45 from $53 and recommends buying shares of Michael Kors (KORS), where he feels the valuation and expectations are lower.
06/01/17
ADAM
06/01/17
NO CHANGE
Target $33
ADAM
Hold
Michael Kors guidance underscores broader challenges ahead, says Canaccord
Canaccord analyst Camilo Lyon noted Michael Kors beat Q4 estimates but said its weaker guidance underscores the broader challenges ahead for the company. Lyon said the company is finally taking aggressive course-correcting action to enhance the brand's position along with cost-savings. The analyst said the macro challenges in the U.S. and Europe remain and there is significant execution risk at hand. Lyon maintained his Hold rating and lowered his price target to $33 from $38 on Michael Kors shares.
07/10/17
MKMP
07/10/17
INITIATION
Target $26
MKMP
Sell
Michael Kors initiated with a Sell at MKM Partners
MKM Partners initiated Michael Kors with a Sell and a $26 price target.
06/01/17
UBSW
06/01/17
NO CHANGE
Target $55
UBSW
Buy
Michael Kors store closures positive for Coach, says UBS
UBS analyst Michael Binetti noted Michael Kors (KORS) announced plans to start closing stores and it is assumed they will be skewed to North America. The analyst believes Michael Kors has been the number one competitive pressure for Coach (COH) over the past five years so its decision to close stores now relieves the company of its number one headwind. He now believes Coach is well positioned as a market share gainer. Binetti reiterated his Buy rating and $55 price target on Coach shares.
ENDP Endo
$9.31

-0.07 (-0.75%)

06/16/17
CANT
06/16/17
INITIATION
Target $12
CANT
Neutral
Endo initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Endo International with a Neutral rating and $12 price target.
06/09/17
06/09/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Snap (SNAP) downgraded to Neutral from Buy at Citi with analyst Mark May saying a slower than expected roll-out of new platforms and channels like self-serve is slowing down the pace of monetization growth. 2. Domino's Pizza (DPZ) downgraded to Neutral from Buy at Longbow with analyst Alton Stump saying his checks indicate second quarter domestic franchised comparables are up 6.25%-6.75%, versus consensus of 7.4%, and recommends investors take a pause on putting new money to work given recent share strength. 3. Nordstrom (JWN) downgraded to Neutral from Buy at Guggenheim with analyst Michael Binetti saying he does not see much further upside potential, even in a leveraged buyout scenario. The analyst believes a going private buyer could only pay $46 per share to generate a 10% internal rate of return. 4. Cantel Medical (CMD) downgraded to Hold from Buy at Benchmark with analyst Raymond Myers saying that he is increasingly concerned that its comparisons become tougher in the next two quarters. 5. Endo (ENDP) downgraded to Hold following Opana ER removal from market at Stifel with analyst Annabel Samimy saying Endo's recovery "just got harder" following the FDA's request for the company to voluntarily remove Opana ER from the market. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/24/17
JANY
07/24/17
NO CHANGE
Target $4
JANY
Buy
BioDelivery Sciences price target raised to $4 from $3 at Janney Capital
Janney Capital analyst Ken Trbovich sees multiple reasons to expect BioDelivery Sciences' Belbuca growth above current levels, including the continued maturing of its newer sales people, the opportunity to secure Medicare coverage contracts and Endo's (ENDP) recent decision to remove Opana ER from the market. He raised his fair value estimate on BioDelivery to $4 from $3 and keeps a Buy rating on the stock.
06/09/17
WBLR
06/09/17
NO CHANGE
WBLR
FDA action on Opana a positive for Collegium, says William Blair
William Blair analyst Tim Lugo views FDA request to remove Endo's (ENDP) Opana ER from the market as a positive for Collegium Pharmaceutical (COLL). The analyst believes Collegium's Xtampza ER has a "best-in-class abuse-deterrent profile." He thinks the drug's scripts could "meaningfully ramp up in the near term." Lugo keeps an Outperform rating on Collegium.
CVS CVS Health
$79.12

(0.00%)

07/28/17
WELS
07/28/17
NO CHANGE
Target $9
WELS
Underperform
Insurers are dropping Valeant's top products, says Wells Fargo
United Healthcare's (UNH) formulary is no longer covering Valeant Pharmaceuticals' (VRX) number three branded drug Solodyn and will also now exclude Retin-A brand, its number four branded drug, Wells Fargo analyst David Maris tells investors in a research note. The analyst estimates the two drugs represented approximately $214M of Valeant's sales in 2016. Maris also points out that Glumetza, Valeant's number eight branded drug, and Relistor were removed in July from CVS/Caremark's (CVS) formulary. These two drugs had approximately $119M in 2016 revenues. Maris notes his counterpart Peter Costa estimates that United Healthcare covers approximately 17% of the U.S. and CVS covers approximately 33%. Express Scripts (ESRX) is releasing its 2018 national formulary next week, Costa adds. Maris keeps an Underperform rating on shares of Valeant with a $9 price target. The stock in premarket trading is down 33c, or 2%, to $16.80.
06/28/17
06/28/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Altaba (AABA) initiated with an Overweight at JPMorgan. 2. Aetna (AET) and Humana (HUM) were initiated with a Buy at Citi. The firm also added Aetna to its Focus List. 3. CVS Health (CVS) and Walgreens Boots Alliance (WBA) were initiated with a Hold at Needham. 4. Oaktree Capital (OAK) initiated with a Hold at Jefferies. 5. General Motors (GM) resumed with an Overweight at Morgan Stanley. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/17
LEER
06/27/17
NO CHANGE
Target $90
LEER
Outperform
CVS gained largest PBM share in 2017 selling season, says Leerink
Leerink analyst David Larsen says his firm's recently published Pharmacy Benefit Manager survey shows that CVS Health is the largest share gainer in the 2017 selling season. The company is poised to win incremental PBM and Specialty Pharmacy share, while the Optum and Cigna deals will start to benefit retail volumes in the near-term, Larsen tells investors in a research note. He keeps an Outperform rating on CVS shares with a $90 price target.
06/27/17
NEED
06/27/17
INITIATION
NEED
Hold
CVS Health initiated with a Hold at Needham
Needham analyst Kevin Caliendo initiated CVS Health with a Hold.
W Wayfair
$80.57

(0.00%)

07/13/17
BUCK
07/13/17
NO CHANGE
Target $95
BUCK
Buy
Wayfair price target raised to $95 from $72 at Buckingham
Buckingham analyst Kelly Halsor reiterates a Buy rating on Wayfair and raised her price target for the shares to $95 from $72. The analyst believes a higher valuation multiple is justified given the reacceleration of direct revenue growth in Q2 and increased acquisition activity by big box retailers.
06/30/17
PIPR
06/30/17
NO CHANGE
Target $87
PIPR
Overweight
Piper analysis shows Wayfair Direct Retail revenue above guidance
Piper Jaffray analyst Peter Keith says his firm's proprietary analysis of Google search trends indicates Wayfair Direct Retail revenue growth of 46% for Q2 versus guidance of 34%-37% and consensus of 40%. The "strong" Direct Retail revenue growth reacceleration is being driven by increased product offerings, exclusivity of products, strategic investments in logistics and supply chain, and increased customer satisfaction due to positive delivery execution, Keith tells investors in a research note. He raised his Q2 revenue estimate to $1.084B, above the consensus of $1.056B, and reiterates an Overweight rating on Wayfair with an $87 price target.
08/03/17
WOLF
08/03/17
INITIATION
Target $88
WOLF
Outperform
Wayfair initiated with an Outperform at Wolfe Research
After the market close last night, Wolfe Research analyst Adrienne Yih started Wayfair with an Outperform rating and $88 price target, calling it the home goods market's "premiere e-commerce growth play."
08/04/17
OPCO
08/04/17
NO CHANGE
Target $88
OPCO
Outperform
Wayfair price target raised to $88 from $80 at Oppenheimer
Oppenheimer analyst Brian Nagel raised his price target for Wayfair to $88 ahead of the company's Q2 results on August 8. Industry data has remained solid while key internal initiatives at Wayfair continue to take hold, Nagel tells investors in a pre-earnings research note. He's "optimistic" that further indications of elevated sales growth should prove another positive, near-term catalyst for shares. Nagel stays Outperform-rated on Wayfair. The online retailer closed yesterday up $3.50 to $77.33.
SEAS SeaWorld
$13.61

(0.00%)

08/03/17
08/03/17
DOWNGRADE
Target $15

Market Perform
SeaWorld downgraded to Market Perform ahead of Q2 results at FBR Capital
FBR Capital analyst Barton Crockett downgraded SeaWorld to Market Perform from Outperform and lowered his price target for the shares to $15 from $20. June data for the San Diego park suggest the new attraction lineup and orca show did not reverse sluggish revenue trends, Crockett tells investors in a research note. He's cautious into the Q2 earnings report. The shares in afternoon trading are down 30c to $13.77.
08/03/17
08/03/17
DOWNGRADE

Market Perform
SeaWorld downgraded to Market Perform from Outperform at FBR Capital
08/01/17
RHCO
08/01/17
NO CHANGE
RHCO
SeaWorld can sell itself or monetize regional parks, says SunTrust
After SeaWorld rallied 7% following a report which stated that the company had hired a strategic adviser, SunTrust analyst Michael A. Swartz says that the company can either sell itself or monetize its regional parks. He estimates that the latter scenario could generate $800M-$1B. The analyst notes that two major shareholders which own a total of roughly 35% of the company could be an obstacle to any deal, and he says that the report, if true, will make investors question the success of its current turnaround plan. He keeps a $22 price target and a Buy rating on the stock.
08/02/17
STFL
08/02/17
NO CHANGE
STFL
SeaWorld CFO change positive, says Stifel
After SeaWorld announced that its CFO, Peter Crage, would leave the company, Stifel analyst Steven M. Wieczynski says the news is positive. The analyst reports that investors believe that Crage did not effectively manage expectations for the company's results. Additionally, the analyst is pleased that the company's CEO will be able to appoint the CFO of his choice. The analyst keeps a $23 price target and a Buy rating on the shares.
DF Dean Foods
$14.97

(0.00%)

08/08/17
SPHN
08/08/17
DOWNGRADE
SPHN
Equal Weight
Dean Foods downgraded to Equal Weight from Overweight at Stephens
08/08/17
JPMS
08/08/17
DOWNGRADE
JPMS
Neutral
Dean Foods downgraded to Neutral from Overweight at JPMorgan
07/27/17
07/27/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. AstraZeneca (AZN) downgraded to Market Perform from Outperform at Leerink with analyst Seamus Fernandez citing the company's "continued reliance on externalization profits and deteriorating earnings quality." 2. F5 Networks (FFIV) was downgraded to Market Perform from Outperform at Wells Fargo and to Perform from Outperform at Oppenheimer. 3. UMC (UMC) was downgraded to Underperform from Neutral at Credit Suisse and to Underperform from Market Perform at Bernstein. 4. U.S. Steel (X) and AK Steel (AKS) were downgraded to Neutral from Buy at Longbow. 5. Dean Foods (DF) downgraded to Underperform from Market Perform at Bernstein with analyst Alexia Howard saying she believes that retailers are increasingly using cheap, private label milk in order to compete with low price competitors. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/27/17
BERN
07/27/17
DOWNGRADE
BERN
Underperform
Dean Foods downgraded to Underperform from Market Perform at Bernstein
Bernstein analyst Alexia Howard downgraded Dean Foods as she believes that retailers are increasingly using cheap, private label milk in order to compete with low price competitors. The analyst expects this change to last longer than in previous cycles. Target to $13 from $18.

TODAY'S FREE FLY STORIES

AMGN

Amgen

$184.86

-1.14 (-0.61%)

12:23
06/23/18
06/23
12:23
06/23/18
12:23
Hot Stocks
Amgen's Repatha 'significantly reduced' LDL-C, non-HDL-C in Type 2 diabetes »

Amgen announced new data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

12:18
06/23/18
06/23
12:18
06/23/18
12:18
Hot Stocks
Eli Lilly's Trulicity shows promise in delivering efficacy in type 2 diabetes »

Two investigational doses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

IRWD

Ironwood

$19.35

0.74 (3.98%)

12:14
06/23/18
06/23
12:14
06/23/18
12:14
Hot Stocks
Ironwood announced Praliciguat phase IIa study data »

Ironwood Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

12:07
06/23/18
06/23
12:07
06/23/18
12:07
Hot Stocks
Array BioPharma announces updated results from Phase 3 BEACON CRC trial »

Array BioPharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

DDAIF

Daimler AG

$0.00

(0.00%)

, BMWYY

BMW

$0.00

(0.00%)

11:42
06/23/18
06/23
11:42
06/23/18
11:42
Periodicals
EU to respond to any U.S. auto tariffs, Reuters reports »

The EU will respond to…

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WBA

Walgreens Boots Alliance

$67.60

-0.2 (-0.29%)

, GE

General Electric

$13.05

0.29 (2.27%)

11:27
06/23/18
06/23
11:27
06/23/18
11:27
Periodicals
Adding Walgreens to Dow may be wrong move, Barron's says »

The guardians of Dow…

WBA

Walgreens Boots Alliance

$67.60

-0.2 (-0.29%)

GE

General Electric

$13.05

0.29 (2.27%)

FB

Facebook

$201.39

-0.07 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

, C

Citi

$67.20

-0.43 (-0.64%)

11:04
06/23/18
06/23
11:04
06/23/18
11:04
Periodicals
Banks to get green light to increase dividends, share repurchases, Barron's says »

Big banks are expected to…

JPM

JPMorgan

$105.73

-1.79 (-1.66%)

C

Citi

$67.20

-0.43 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Jul

  • 26

    Jul

  • 12

    Oct

  • 14

    Jan

  • 15

    Apr

  • 13

    Jul

  • 15

    Oct

MD

Mednax

$44.99

-0.11 (-0.24%)

10:59
06/23/18
06/23
10:59
06/23/18
10:59
Periodicals
Mednax shares may be at risk amid hospital fights, Barron's says »

After peaking in 2015,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

10:25
06/23/18
06/23
10:25
06/23/18
10:25
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

TWTR

Twitter

$45.90

0.68 (1.50%)

, FOXA

21st Century Fox

$48.59

0.25 (0.52%)

10:21
06/23/18
06/23
10:21
06/23/18
10:21
Periodicals
Biggest winner of World Cup could be Twitter, Barron's says »

Twitter's (TWTR)…

TWTR

Twitter

$45.90

0.68 (1.50%)

FOXA

21st Century Fox

$48.59

0.25 (0.52%)

AMZN

Amazon.com

$1,715.07

-15.13 (-0.87%)

FB

Facebook

$201.39

-0.07 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AAPL

Apple

$184.85

-0.63 (-0.34%)

, DDAIF

Daimler AG

$0.00

(0.00%)

10:10
06/23/18
06/23
10:10
06/23/18
10:10
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AAPL

Apple

$184.85

-0.63 (-0.34%)

DDAIF

Daimler AG

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

VLKAY

Volkswagen

$0.00

(0.00%)

ZTCOY

ZTE Corp.

$0.00

(0.00%)

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

STMP

Stamps.com

$252.60

0.65 (0.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

A

Agilent

$62.79

-0.24 (-0.38%)

, ABT

Abbott

$61.93

0.19 (0.31%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
American Diabetes Association to hold a conference »

78th Scientific Sessions…

A

Agilent

$62.79

-0.24 (-0.38%)

ABT

Abbott

$61.93

0.19 (0.31%)

AKCA

Akcea Therapeutics

$26.24

0.4 (1.55%)

AMGN

Amgen

$184.86

-1.14 (-0.61%)

AZN

AstraZeneca

$35.06

-0.095 (-0.27%)

BAYRY

Bayer

$0.00

(0.00%)

CL

Colgate-Palmolive

$64.63

1.15 (1.81%)

DXCM

DexCom

$99.52

-0.2 (-0.20%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

IRWD

Ironwood

$19.35

0.74 (3.98%)

JNJ

Johnson & Johnson

$122.81

1.36 (1.12%)

MDT

Medtronic

$86.80

0.51 (0.59%)

MNKD

MannKind

$1.98

0.02 (1.02%)

WAKE

Wake Forest Bancshares Inc.

$0.00

(0.00%)

VLRX

Valeritas

$1.39

0.035 (2.58%)

TNDM

TNDM

SNY

Sanofi

$39.98

0.96 (2.46%)

SIEGY

Siemens

$0.00

(0.00%)

SENS

Senseonics

$4.76

-0.2 (-4.03%)

REGN

Regeneron

$331.82

2.81 (0.85%)

PODD

Insulet

$97.37

0.5697 (0.59%)

NVO

Novo Nordisk

$46.84

0.435 (0.94%)

MRK

Merck

$61.46

0.295 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 25

    Jun

  • 26

    Jun

  • 28

    Jun

  • 02

    Jul

  • 06

    Jul

  • 12

    Jul

  • 17

    Jul

  • 18

    Jul

  • 11

    Aug

  • 27

    Aug

  • 30

    Aug

  • 10

    Sep

  • 06

    Oct

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 28

    Jan

  • 22

    Mar

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
Array BioPharma to hold a conference call »

In conjunction with the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 30

    Jun

  • 30

    Jun

ICE

IntercontinentalExchange

$74.81

-0.11 (-0.15%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
IntercontinentalExchange management to meet with UBS »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

AMGN

Amgen

$184.86

-1.14 (-0.61%)

, ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

04:55
06/23/18
06/23
04:55
06/23/18
04:55
Conference/Events
European Society for Medical Oncology (ESMO) to hold a conference »

ESMO World Congress on…

AMGN

Amgen

$184.86

-1.14 (-0.61%)

ARRY

Array BioPharma

$19.37

-0.19 (-0.97%)

BAYRY

Bayer

$0.00

(0.00%)

HALO

Halozyme

$18.07

-0.52 (-2.80%)

INCY

Incyte

$74.02

1.55 (2.14%)

LLY

Eli Lilly

$85.90

-0.17 (-0.20%)

MRK

Merck

$61.46

0.295 (0.48%)

SHPG

Shire

$161.73

-0.7 (-0.43%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$39.98

0.96 (2.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 28

    Jun

  • 30

    Jun

  • 30

    Jun

  • 10

    Sep

  • 20

    Oct

  • 23

    Oct

  • 28

    Oct

  • 21

    Dec

  • 28

    Jan

  • 22

    Mar

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

, PCG

PG&E

$42.98

2.44 (6.02%)

18:17
06/22/18
06/22
18:17
06/22/18
18:17
Hot Stocks
Northwest Natural to sell Gill Ranch Storage to SENSA Holdings »

NW Natural (NWN)…

NWN

Northwest Natural Gas

$62.63

0.075 (0.12%)

PCG

PG&E

$42.98

2.44 (6.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

ORLY

O'Reilly Automotive

$285.90

-1.18 (-0.41%)

18:03
06/22/18
06/22
18:03
06/22/18
18:03
Hot Stocks
O'Reilly Automotive's O'Reilly sells 19,250 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$33.15

0.02 (0.06%)

17:46
06/22/18
06/22
17:46
06/22/18
17:46
Hot Stocks
South Jersey Industries announces approval of Elizabethtown Gas purchase »

South Jersey Industries…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WAAS

AquaVenture

$15.36

0.12 (0.79%)

17:27
06/22/18
06/22
17:27
06/22/18
17:27
Hot Stocks
AquaVenture extends long-stop date for Ghana plant acquisition to September 30 »

AquaVenture announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NSANY

Nissan

$0.00

(0.00%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Periodicals
Nissan chooses Thailand for hybrid's first export market, Nikkei reports »

Nissan has planned to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TROV

Trovagene

$0.81

-0.0068 (-0.83%)

17:22
06/22/18
06/22
17:22
06/22/18
17:22
Hot Stocks
Trovagene CEO William Welch resigns, Dr. Thomas Adams named interim CEO »

Trovagene announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CVM

CEL-SCI

$3.26

0.005 (0.15%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Syndicate
Breaking Syndicate news story on CEL-SCI »

CEL-SCI files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

$33.49

-0.15 (-0.45%)

17:19
06/22/18
06/22
17:19
06/22/18
17:19
Hot Stocks
Aecom to compete for $148.5M U.S. Army contract »

AECOM-Baker JV, Bryan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:17
06/22/18
06/22
17:17
06/22/18
17:17
Hot Stocks
Lockheed Martin awarded $175.3M U.S. Navy contract modification »

Lockheed Martin is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

LMT

Lockheed Martin

$298.95

-1.39 (-0.46%)

17:16
06/22/18
06/22
17:16
06/22/18
17:16
Hot Stocks
Lockheed Martin awarded $1.12B U.S. Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.